Up almost 1000% in 1 year, the Bionomics (ASX:BNO) share price moves higher

The Bionomics Ltd (ASX: BNO) share price is in positive territory after announcing a non-renounceable entitlement offer. Here’s the details.

| More on:
Five stacked building blocks with green arrows, indicating rising inflation or share prices

Image source: Getty Images

The Bionomics Ltd (ASX: BNO) share price is in positive territory today after announcing a non-renounceable entitlement offer. During mid-afternoon trade, the clinical-stage biopharmaceutical company’s shares are up 3.5% to 30 cents.

This takes the Bionomics share price to more than a 950% gain when compared to this time last year. Surprisingly, in March 2020, the company’s shares were swapping hands for as little as 2.8 cents.

Details of the offer

In its announcement, Bionomics updated shareholders advising of a pro rata non- renounceable entitlement offer on a 1:6 basis. This follows the company’s recent subscribed underwritten placement to North American and European institutional and sophisticated investors.

The offer price will be issued at the same rate to the previous placement, at 14.5 cents apiece. Notably, this represents a 50% discount on the current Bionomics share price of 29.5 cents. Moreover, the new shares will rank equally with existing ordinary shares.

The record date for the entitlement offer is on Thursday 11 March, 6:00pm Australian Central Daylight Time (ACDT). Unless extended, the placement will close 30 March, 5:00pm ACDT. The new shares will be allotted on 8 April 2021.

The expected take-up of the offer is estimated to bring in around $20 million in capital for the company. This will be used to partly fund a Phase 2b Post-Traumatic Stress Disorder trial for mid-2021. Additionally, the remaining monies will be spent towards general working capital purposes.

Quick take on Bionomics

Founded in 1996, Bionomics is a biopharmaceutical company that develops drug candidates to treat central nervous system disorders. This includes anxiety, depression, and Alzheimer’s disease.

The company has offices in Australia, the United States, and France.

About the Bionomics share price

Over the last 12 months, the Bionomics share price has been one of the best performers on the ASX market. Positive investor sentiment in the company picked up towards September, and particularly shot higher in February.

Based on current valuations, Bionomics has a market capitalisation of close to $250 million.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Top 10 - asx shares today
Share Market News

Here are the top 10 ASX shares today

Today, the S&P/ASX 200 Index (ASX: XJO) fought back against the selling pressure throughout the day to finish in the green. …

Read more »

The word inflation written with a ticking time bomb.
Share Market News

Why is it when Jerome Powell sneezes, the ASX 200 catches a cold?

Key points The ASX 200 took a hit following comments from the United States Federal Reserve chair Jerome Powell Expectations …

Read more »

blue arrows representing a rising share price ASX 200
Share Market News

These 3 ASX 200 shares are topping the volume charts this Friday

Finally, a day of green for ASX shares! The S&P/ASX 200 Index (ASX: XJO) is bouncing back strongly today, after a …

Read more »

Young boy wearing suit and glasses adds up on calculator with coins on table
Share Market News

This world-famous fund manager is ‘buying the dip’. Here’s why

Key points Bill Ackman is one of the most famous fund managers in the world He runs Pershing Square Capital …

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices
Share Market News

ASX 200 (ASX:XJO) midday update: ResMed and PointsBet disappoint

At lunch on Friday, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a much-needed positive …

Read more »

A man activates an arrow shooting up into a cloud sign on his phone, indicating share price movement in ASX tech shares
Share Market News

Is the Betashares Nasdaq 100 ETF (ASX:NDQ) an opportunity in this market correction?

Could the Betashares Nasdaq 100 ETF (ASX: NDQ) be a good opportunity during this correction for both the global share …

Read more »

A woman shouts through a megaphone.
Share Market News

2 ASX growth shares to buy in February with 40% upside

If you’re looking to make some additions to your portfolio in February, then the two ASX shares listed below could …

Read more »

Business woman watching stocks and trends while thinking
Share Market News

5 things to watch on the ASX 200 on Friday

On Thursday, the S&P/ASX 200 Index (ASX: XJO) fought hard and was able to record a small gain. The benchmark index rose …

Read more »